Lucy Therapeutics
Chief Executive Officer Amy has over 20 years of drug discovery experience and was involved in the discovery of two marketed drugs (Daklinza® and Sunvepra®). She has participated in 5 biotech INDs and has more than 30 issued patents. She has held VP and Executive Director positions at prominent CROs. Amy has chaired the prestigious Medicinal Chemistry Gordon Conference and currently serves on the Scientific Advisory Boards of Q Biomed Ventures and Rheostat Therapeutics.
Lucy Therapeutics
Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.